AU2005209256B2 - Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis - Google Patents
Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis Download PDFInfo
- Publication number
- AU2005209256B2 AU2005209256B2 AU2005209256A AU2005209256A AU2005209256B2 AU 2005209256 B2 AU2005209256 B2 AU 2005209256B2 AU 2005209256 A AU2005209256 A AU 2005209256A AU 2005209256 A AU2005209256 A AU 2005209256A AU 2005209256 B2 AU2005209256 B2 AU 2005209256B2
- Authority
- AU
- Australia
- Prior art keywords
- mmtv
- tenofovir
- adefovir
- breast cancer
- pbc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53806604P | 2004-01-21 | 2004-01-21 | |
| US60/538,066 | 2004-01-21 | ||
| PCT/US2005/002043 WO2005072748A1 (en) | 2004-01-21 | 2005-01-21 | Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005209256A1 AU2005209256A1 (en) | 2005-08-11 |
| AU2005209256B2 true AU2005209256B2 (en) | 2010-11-18 |
Family
ID=34825960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005209256A Ceased AU2005209256B2 (en) | 2004-01-21 | 2005-01-21 | Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070281911A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1732569B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007518815A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE445404T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005209256B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2553455A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005017131D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2334149T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ548532A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005072748A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1879657A2 (en) * | 2005-04-25 | 2008-01-23 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
| RU2301088C2 (ru) * | 2005-09-01 | 2007-06-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения рецидива рака молочной железы |
| ATE534377T1 (de) | 2006-05-16 | 2011-12-15 | Gilead Sciences Inc | Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen |
| ES2566762T3 (es) * | 2009-10-05 | 2016-04-15 | Ambergen Inc. | Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| GB201509431D0 (en) * | 2015-06-01 | 2015-07-15 | Equigerminal Sa | Antiviral composition |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| KR102196711B1 (ko) * | 2018-08-30 | 2020-12-30 | 가톨릭대학교 산학협력단 | 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물 |
| WO2020171225A1 (ja) * | 2019-02-22 | 2020-08-27 | 一素 村田 | mTOR阻害剤 |
| US12029783B2 (en) | 2019-07-02 | 2024-07-09 | Virago Vax Inc. | Mammary tumor virus vaccine |
| US12016844B2 (en) | 2019-07-02 | 2024-06-25 | Virago Vax Inc. | Mammary tumor virus suppression |
| EP3993873A4 (en) * | 2019-07-02 | 2023-09-20 | Virago Vax Inc. | SUPPRESSION OF BREAST TUMORS |
| CN119546620A (zh) | 2022-03-15 | 2025-02-28 | 罗梅治疗股份有限公司 | 用于治疗疾病的化合物和方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000829A2 (en) * | 1999-06-30 | 2001-01-04 | Tulane University Medical Center | Human endogenous retrovirus in breast cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073507A2 (en) * | 1999-06-01 | 2000-12-07 | Alton Ochsner Medical Foundation | Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
| HRP20030047B1 (hr) * | 2000-07-21 | 2016-02-26 | Gilead Sciences, Inc. | Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava |
| IL164809A0 (en) * | 2002-05-13 | 2005-12-18 | Metabasis Therapeutics Inc | Novel phosphonic acid basdrugs of pmea and its analogues |
-
2005
- 2005-01-21 CA CA002553455A patent/CA2553455A1/en not_active Abandoned
- 2005-01-21 AU AU2005209256A patent/AU2005209256B2/en not_active Ceased
- 2005-01-21 AT AT05706024T patent/ATE445404T1/de not_active IP Right Cessation
- 2005-01-21 EP EP05706024A patent/EP1732569B1/en not_active Expired - Lifetime
- 2005-01-21 JP JP2006551327A patent/JP2007518815A/ja active Pending
- 2005-01-21 US US10/586,627 patent/US20070281911A1/en not_active Abandoned
- 2005-01-21 WO PCT/US2005/002043 patent/WO2005072748A1/en not_active Ceased
- 2005-01-21 DE DE602005017131T patent/DE602005017131D1/de not_active Expired - Lifetime
- 2005-01-21 ES ES05706024T patent/ES2334149T3/es not_active Expired - Lifetime
- 2005-01-21 NZ NZ548532A patent/NZ548532A/en unknown
- 2005-01-21 US US11/040,929 patent/US20050239753A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000829A2 (en) * | 1999-06-30 | 2001-01-04 | Tulane University Medical Center | Human endogenous retrovirus in breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE445404T1 (de) | 2009-10-15 |
| CA2553455A1 (en) | 2005-08-11 |
| EP1732569B1 (en) | 2009-10-14 |
| US20050239753A1 (en) | 2005-10-27 |
| HK1099228A1 (en) | 2007-08-10 |
| AU2005209256A1 (en) | 2005-08-11 |
| EP1732569A1 (en) | 2006-12-20 |
| JP2007518815A (ja) | 2007-07-12 |
| ES2334149T3 (es) | 2010-03-05 |
| WO2005072748A1 (en) | 2005-08-11 |
| US20070281911A1 (en) | 2007-12-06 |
| DE602005017131D1 (de) | 2009-11-26 |
| NZ548532A (en) | 2009-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1732569B1 (en) | Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis | |
| Lin et al. | Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: Structure–activity relationships | |
| HUE026849T2 (en) | Therapeutic combination containing dolutegravir, abacavir and lamivudine | |
| JP2001500471A (ja) | プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法 | |
| CA2853495A1 (en) | Methods and compositions for treating hepatitis c virus | |
| US20250099476A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
| JP2020203947A (ja) | Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法 | |
| WO2013012477A1 (en) | Propolis and caffeic acid phenethyl ester and uses thereof | |
| US20230158103A1 (en) | Pld for use in combination in the treatment of coronavirus | |
| MX2010010082A (es) | Utilización de 4'-thio-2'-deoxinucleótidos como agentes anti-orthopoxvirus. | |
| WO2015120057A1 (en) | Pharmaceutical combinations against co-infection with hiv and tuberculosis | |
| CN111587107B (zh) | 药物组合物 | |
| HK1099228B (en) | Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis | |
| US7615542B2 (en) | Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV | |
| CA2501717C (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| CN1302779C (zh) | 含有阿巴卡韦和阿洛夫定的药物制剂及其用途 | |
| CN114903891B (zh) | 沙奎那韦在治疗或预防乙型肝炎中的应用 | |
| US12616692B2 (en) | Method of achieving HIV viral remission using long-acting antiretroviral agents | |
| CN114099517B (zh) | 苯并咪唑类化合物在治疗或预防乙型肝炎中的应用 | |
| AU2017268621A1 (en) | Antiviral therapy | |
| Foggia et al. | Tenofovir disoproxil fumarate in the clinical practice: An overview | |
| CN115518072A (zh) | 一种用于治疗病毒性肝炎的药物组合物 | |
| CN110623968A (zh) | 伊文思蓝在制备药物中的用途及药物组合物 | |
| US20090291908A1 (en) | Use of thiophoshonoformic acid and nrtis to treat viral infections | |
| Khoury et al. | ODE-adefovir exhibits potent in vitro and in vivo cytotoxic activity and has synergistic effect with ara-c in AML |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |